New study: arthritis drug baricitinib may lower heart risks
NCT ID NCT07357649
First seen Feb 01, 2026 · Last updated May 10, 2026 · Updated 13 times
Summary
This study looks at whether baricitinib, a drug for rheumatoid arthritis, can improve blood clotting and cholesterol levels better than standard treatments. About 100 adults with active rheumatoid arthritis will take baricitinib or continue their usual therapy for 3 months. Researchers will measure changes in clotting markers and cholesterol to see if baricitinib offers extra heart-related benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta University Hospitals
Tanta, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.